Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.40 |
| ▸ | CCR2 | P41597 | 1/20 | 0.40 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14453910 | 1.00 | KCNH2 (0.40) | KCNH2CCR2TLR9TLR8TLR7 | |
| SCHEMBL23594008 | 1.00 | KCNH2 (0.40) | KCNH2CCR2TLR9TLR8TLR7 | |
| SCHEMBL14453909 | 0.90 | CHRM5 (0.41) | KCNH2TLR9TLR8TLR7HRH3 | |
| SCHEMBL26462407 | 0.89 | CCR2 (0.39) | KCNH2CCR2TLR9TLR8TLR7 | |
| SCHEMBL25565485 | 0.89 | KCNH2 (0.36) | KCNH2CCR2TLR9TLR8TLR7 | |
| SCHEMBL25461036 | 0.89 | HRH3 (0.40) | KCNH2CCR2TLR9TLR8TLR7 | |
| SCHEMBL26462397 | 0.89 | CCR2 (0.39) | KCNH2CCR2TLR9TLR8TLR7 | |
| SCHEMBL23205756 | 0.89 | CHRM5 (0.47) | KCNH2CCR2TLR9TLR8TLR7 | |
| SCHEMBL15242464 | 0.89 | CHRM5 (0.47) | KCNH2CCR2TLR9TLR8TLR7 | |
| SCHEMBL24233173 | 0.88 | ACHE (0.44) | KCNH2TLR9TLR8TLR7HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | NURIX THERAPEUTICS, INC. (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135894-A1 | MK2 DEGRADERS AND USES THEREOF | MKNK2, MKRN3, DUS2 | KCNH2 3085/4885CCR2 3286/4885TLR9 4051/4885 |
| US-11820781-B2 | Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway | BTK, CBL, XIAP | KCNH2 4713/4885CCR2 3643/4885TLR9 3573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.